GlaxoSmithKline

June 16, 2014November 11, 2015

GSK’s Incruse Ellipta Shows Positive Results In Phase 3 COPD Trial

COPD, News

GlaxoSmithKline and Theravance recently announced positive results of a Phase 3 trial that tested Incruse Ellipta as a combined treatment for chronic obstructive pulmonary disease (COPD). The Phase 3 trial consisted ... Read more

May 30, 2014November 11, 2015

GSK’s Incruse Ellipta Approved By FDA For Treating Chronic Bronchitis, Emphysema, COPD

Chronic Bronchitis, COPD, Emphysema, News

The U.S. Food and Drug Administration (FDA) recently authorized Incruse Ellipta for the treatment of airflow obstruction in patients who suffer from chronic obstructive pulmonary disease (COPD), as well as ... Read more

May 20, 2014November 11, 2015

Anoro COPD Treatment Gets Marketing Authorization in Europe

COPD, News

The European Commission has granted marketing authorization for Anoro (Umeclidinium/Vilanterol), a chronic obstructive pulmonary disease (COPD) treatment, which is currently licensed in Europe as UMEC/VI55mcg/22mcg. GlaxoSmithKline and Theravance announced the now-authorized combination ... Read more